RESUMO
Background: Hospital-at-Home (HAH) is a valid alternative for in-hospital stay for a wide variety of clinical indications. Occult myocardial injury, associated with acute illness, mainly occurs in patients with a background of non-obstructive coronary disease. The aim of this study was to describe the prevalence of this phenomenon in our HAH population. Methods: A retrospective description and analysis of data collected for patients admitted to the Sheba beyond's HAH services during 14 months. Results: During a period of 14 months (7/10/21-6/12/22), blood troponin measurements were available for 213 patients (median age 78 years, 52% males) hospitalized mainly for infectious causes. The median HS (highly sensitive) troponin level was 7.7 ng/L (IQR = 13.2 ng/L) (the normal upper limit is 12 ng/L) with 31% of all patients demonstrating an abnormally increased troponin level (68/213). Of all patients, 64% had a background diagnosis of a cardiovascular disease (138/213), of whom, 49% had abnormal HS troponin levels (68/138). No patient suffered from acute cardiac function deterioration and no patient died during their hospital-at-home stay. Conclusion: The prevalence of occult myocardial injury amongst elderly patients admitted to hospital-at-home stay for diagnoses other than myocardial infarction is relatively high but it is not associated with worse short-term clinical outcomes.
RESUMO
The spleen tyrosine kinase (Syk) inhibitor R406 is orally administered as the prodrug R788. Following administration of R788 (12.5 mg kg(-1), 20 microCi kg(-1 14)C-R788) to intact and bile duct-cannulated cynomolgus monkeys, drug-related radioactivity was rapidly observed in plasma. No R788 was observed in plasma, while R406 was the major radioactive peak observed at all time points. Only low levels of metabolites were observed in plasma. The half-life for plasma radioactivity was 2.0-2.8 h. The majority (68.9%) of drug-related radioactivity was eliminated into bile. No intact R406 was observed in excreta. Biliary and urinary metabolites consisted of glucuronide and sulfate conjugates of the para-O-demethylated metabolite of R406 (R529), and a direct N-glucuronide of R406. The major metabolite in faeces from intact and bile duct-cannulated monkeys was a unique 3,5-benzene diol metabolite of R406. This metabolite was formed following the sequential O-demethylation and para-dehydroxylation of R529 by anaerobic gut bacteria.
Assuntos
Bile/química , Peptídeos e Proteínas de Sinalização Intracelular/antagonistas & inibidores , Macaca fascicularis/metabolismo , Oxazinas/sangue , Oxazinas/metabolismo , Proteínas Tirosina Quinases/antagonistas & inibidores , Piridinas/sangue , Piridinas/metabolismo , Administração Oral , Aminopiridinas , Animais , Bactérias Anaeróbias/metabolismo , Radioisótopos de Carbono/sangue , Fezes/química , Fezes/microbiologia , Intestinos/microbiologia , Macaca fascicularis/microbiologia , Masculino , Morfolinas , Oxazinas/análise , Oxazinas/farmacologia , Piridinas/análise , Piridinas/farmacologia , Pirimidinas , Quinase SykRESUMO
Human brain natriuretic peptide (hBNP) has demonstrated favorable hemodynamic effects in patients with congestive heart failure; however, the peptidic nature of this compound has focused clinical testing on protocols involving intravenous delivery. We have studied subcutaneous delivery as an alternative method of administering hBNP. Administration of 30 microgram/kg hBNP by either subcutaneous or intravenous delivery protocols resulted in significant hBNP-immunoreactive material in the plasma with area under the plasma concentration-time curve values of 310 +/- 20 nmolxmins/liter and 187 +/- 47 nmolxmins/liter, respectively. Plasma cyclic GMP, a surrogate marker of activation of the biological receptor for hBNP, was elevated for a longer period of time following subcutaneous delivery compared with intravenous delivery. Subcutaneous delivery of 30 microg/kg hBNP resulted in natriuresis, diuresis and reduced systolic blood pressure in anesthetized normotensive rabbits, effects similar in magnitude yet prolonged in duration compared with those elicited by the same dose of hBNP delivered intravenously. Systolic blood pressure following hBNP treatment remained below base-line values for 50 and 150 min following intravenous and subcutaneous delivery protocols, respectively. These results suggests that subcutaneous delivery of hBNP may be a viable therapeutic alternative to intravenous modes of delivery.
Assuntos
Peptídeo Natriurético Encefálico/farmacocinética , Sequência de Aminoácidos , Animais , Pressão Sanguínea/efeitos dos fármacos , GMP Cíclico/sangue , Humanos , Injeções Subcutâneas , Rim/efeitos dos fármacos , Masculino , Dados de Sequência Molecular , Peptídeo Natriurético Encefálico/administração & dosagem , Peptídeo Natriurético Encefálico/farmacologia , CoelhosRESUMO
Human brain natriuretic peptide (hBNP) is a cardiac-derived peptide hormone with potent hemodynamic and renal effects in dogs, monkeys, and humans, but not in rats. At present there is no small animal model to study the actions of hBNP. These studies describe the effects of hBNP in New Zealand White rabbits in normotensive and acute norepinephrine-induced hypertensive states. Intravenous administration of hBNP (1, 3, 10, and 30 microg/kg) to anesthetized rabbits resulted in a dose-dependent diuresis and natriuresis and a decrease in systolic blood pressure. Bolus administration of hBNP resulted in a time- and dose-dependent accumulation of plasma cyclic GMP, consistent with activation of a particulate guanylyl cyclase receptor. The hemodynamic actions of hBNP suggest clinical utility for the management of acute hypertension associated with numerous surgical procedures, a condition linked to catecholamine activation. In rabbits with norepinephrine-induced acute hypertension, bolus and continuous infusion of hBNP markedly reduced blood pressure. These studies demonstrate that the rabbit is a useful species to study the hemodynamic and renal effects of hBNP and that this peptide may have therapeutic utility for the acute reduction of hypertension associated with catecholamine activation.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Hipertensão Renovascular/fisiopatologia , Proteínas do Tecido Nervoso/administração & dosagem , Norepinefrina , Animais , Cães , Humanos , Hipertensão Renovascular/induzido quimicamente , Hipertensão Renovascular/tratamento farmacológico , Peptídeo Natriurético Encefálico , Coelhos , RatosRESUMO
Synthetic human brain natriuretic peptide (sBNP) is a polypeptide with the same amino acid sequence as the naturally occurring hormone. Preclinical studies have demonstrated that BNP has potent hemodynamic, diuretic, and natriuretic effects that might be beneficial in treating patients with heart failure. This study was a randomized, double-blind, placebo-controlled, ascending-dose trial of sBNP administered as a single intravenous bolus in 27 heart failure patients. Six groups of patients received sequentially increasing doses of sBNP (0.3, 1, 3, 10, 15, and 20 micrograms/kg, respectively) as a single intravenous injection, and hemodynamics were assessed by pulmonary artery monitoring catheter. The 10 and 15 micrograms/kg doses of sBNP resulted in significant reductions in pulmonary capillary wedge pressure (-73%, p < 0.001), mean pulmonary artery pressure (-41%, p < 0.001), mean arterial blood pressure (-28%, p = 0.001), and systemic vascular resistance (-53%, p = 0.004). Significant increases occurred in cardiac index (68%, p < 0.001) and stroke volume index (72%, p < 0.001). The magnitude and duration of hemodynamic changes were dose dependent. There were no adverse effects. sBNP injected as a single intravenous bolus in heart failure patients improves hemodynamics in a dose-related fashion. Further clinical investigations to determine the use of sBNP in decompensated heart failure are clearly warranted.
Assuntos
Cardiomiopatia Dilatada/fisiopatologia , Insuficiência Cardíaca/fisiopatologia , Hemodinâmica/efeitos dos fármacos , Proteínas do Tecido Nervoso/farmacologia , Cardiomiopatia Dilatada/complicações , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Insuficiência Cardíaca/etiologia , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico , Proteínas do Tecido Nervoso/administração & dosagemRESUMO
OBJECTIVE: To evaluate the efficacy of a novel, oxygen-transporting perfluorochemical emulsion as a prehospital therapy, using a canine hemorrhagic shock model based on compromised tissue oxygenation. DESIGN: Prospective, randomized, controlled study. SETTING: HemaGen animal laboratory. SUBJECTS: Sixteen healthy, adult male grade beagles (weight 8 to 14 kg). INTERVENTIONS: Administration of lactated Ringer's solution (n = 8), 15 mL/kg and perfluorochemical emulsion admixed with physiologic salts (n = 8), 15 mL/kg. MEASUREMENTS AND MAIN RESULTS: PaO2 increased significantly (p < .01) in the perfluorochemical-treated animals for 2 hrs after resuscitation. Mixed venous PO2 returned to preshock values in the perfluorochemical-treated dogs for 60 mins after fluid administration (p < .01). Normalization of hemodynamic variables was not observed in either group. Although not statistically significant, survival of the lactated Ringer's solution-treated animals was 63% compared with 100% for the perfluorochemical-treated dogs at 3 hrs after resuscitation. CONCLUSIONS: Resuscitation with a perfluorochemical emulsion augmented oxygen transport and restored global tissue oxygenation after massive hemorrhage, which translated into improved survival when compared with the group receiving an equal volume of lactated Ringer's solution.
Assuntos
Fluorocarbonos/administração & dosagem , Ressuscitação/métodos , Choque Hemorrágico/terapia , Animais , Cães , Avaliação Pré-Clínica de Medicamentos , Emulsões , Hemodinâmica , Soluções Isotônicas , Masculino , Oxigênio/metabolismo , Estudos Prospectivos , Distribuição Aleatória , Lactato de Ringer , EsplenectomiaRESUMO
Sera from over 1,600 patients who received recombinant human tissue plasminogen activator (rt-PA) during clinical trials were assessed for the presence of antibodies to this therapeutic agent. The rt-PA was administered by a variety of dosage regimens for several different indications. Two different forms of rt-PA were used; one was predominantly two chain form, and the other was a predominantly one chain form. A sensitive radioimmunoprecipitation assay was used to measure antibodies to rt-PA in patients' serum before and after treatment. Of 932 patients tested with this assay, 929 were negative for antibodies to t-PA. Three patients developed low titers after treatment. Additional serum samples were obtained from these three patients within 2 years after rt-PA therapy and were negative for antibodies to t-PA. With the limited number of positive samples, no correlation could be found with dose or type of rt-PA, dosing regimen or clinical diagnosis. The virtual absence of antibody formation was confirmed in an additional 754 patients using a novel competitive two-site ELISA. It can be concluded that a single infusion of rt-PA was virtually unassociated with antibody formation, suggesting that repeat treatments could be given when necessary without the risk of immunologic complications as are seen with streptokinase or its derivatives.
Assuntos
Anticorpos/sangue , Ativador de Plasminogênio Tecidual/imunologia , Animais , Callitrichinae , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/imunologia , Ensaio de Imunoadsorção Enzimática , Estudos de Avaliação como Assunto , Humanos , Ensaio de Radioimunoprecipitação , Ratos , Proteínas Recombinantes/imunologia , Proteínas Recombinantes/uso terapêutico , Ativador de Plasminogênio Tecidual/uso terapêuticoRESUMO
Thrombolytic therapy has received renewed attention with the demonstration that early treatment of acute myocardial infarction with plasminogen activators can reduce mortality. Tissue plasminogen activator (t-PA) is a protein with attributes that may allow for greater efficacy and safety. Recombinant DNA technology has enabled the production of sufficient t-PA, called rt-PA (Activase), for substantial clinical evaluation. The results suggest that Activase is a significant advance in thrombolytic therapy.
Assuntos
Ativador de Plasminogênio Tecidual/farmacologia , Humanos , Masculino , Proteínas Recombinantes/farmacologiaRESUMO
Twenty-four patients with unstable angina pectoris, defined as chest pain at rest with transient ST segment deviation of at least 1 mm, were randomly assigned to blinded treatment with either placebo or intravenous recombinant human tissue-type plasminogen activator (rt-PA). Before randomization, all patients were treated with oral beta-blockers, calcium antagonists, nitrates, and continuous intravenous heparin for a monitoring period of 12 to 28 hr. After this monitoring period the 24 patients were randomly assigned to receive either placebo or 1.75 mg/kg intravenous rt-PA given over 12 hr at a rate of 0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr. One patient, assigned to receive placebo, developed acute myocardial infarction after randomization but before receiving the study drug. Ischemic events were recorded during a hospital follow-up period of at least 4 days unless a further intervention was indicated or the coronary angiogram was normal. The follow-up period was 7 +/- 5 days (mean +/- SD) after the placebo infusion and 8 +/- 4 days after the infusion of rt-PA. Unstable angina pectoris persisted after the completion of the infusion in six of 11 patients receiving placebo and only one of 12 patients receiving rt-PA (p less than .03). Coronary angiography, performed 38 +/- 19 hr after the infusion, demonstrated subocclusive thrombus in eight of 11 patients receiving placebo but in none of 11 patients treated with rt-PA (p less than .002). One patient on rt-PA refused coronary angiography.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Angina Pectoris/tratamento farmacológico , Angina Instável/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Angina Instável/sangue , Angina Instável/complicações , Coagulação Sanguínea/efeitos dos fármacos , Ensaios Clínicos como Assunto , Angiografia Coronária , Método Duplo-Cego , Eletrocardiografia , Humanos , Monitorização Fisiológica , Placebos , Estudos Prospectivos , Distribuição Aleatória , Proteínas Recombinantes/uso terapêutico , Fatores de TempoRESUMO
A new, predominantly single chain preparation of recombinant tissue-type plasminogen activator was evaluated to determine coronary thrombolytic efficacy in 100 patients with acute myocardial infarction. At 3.6 +/- 1.2 hours (mean +/- SD) from symptom onset, patients received either intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours) or placebo on a 3:1 randomized, double-blind basis. Coronary angiography, performed 68 +/- 13 minutes after initiation of the study drug infusion, demonstrated patency of the infarct-related artery in 40 (57%) of 70 patients in the tissue plasminogen activator group compared with 3 (13%) of 23 patients in the placebo group (p less than 0.001). Patients in the placebo group were then eligible to receive intracoronary streptokinase. At 90 minutes the patency was observed in 49 (69%) of 71 tissue plasminogen activator patients compared with 5 (24%) of 21 placebo patients (p less than 0.001). At 120 minutes patency was observed in 59 (79%) of 75 patients of the tissue plasminogen activator group and in 10 (40%) of 25 in the intracoronary streptokinase/placebo group. A nadir value of less than 100 mg/dl fibrinogen occurred in 8 (11%) of 73 patients receiving tissue plasminogen activator versus 8 (40%) of 20 patients treated with intracoronary streptokinase (p = 0.002). Moderate or severe bleeding episodes occurred in 39% of patients treated with tissue plasminogen activator compared with 32% of patients who received placebo/intracoronary streptokinase (p = NS). Thus, this tissue plasminogen activator preparation achieves a high rate of recanalization and, at the doses employed, exhibits increased fibrinogen sparing compared with intracoronary streptokinase.
Assuntos
Infarto do Miocárdio/tratamento farmacológico , Recombinação Genética , Ativador de Plasminogênio Tecidual/uso terapêutico , Angiografia , Angioplastia com Balão , Anticorpos/análise , Antígenos/análise , Ensaios Clínicos como Assunto , Hemorragia/induzido quimicamente , Humanos , Injeções Intravenosas , Infarto do Miocárdio/diagnóstico por imagem , Infarto do Miocárdio/fisiopatologia , Infarto do Miocárdio/terapia , Placebos , Distribuição Aleatória , Ativador de Plasminogênio Tecidual/efeitos adversos , Ativador de Plasminogênio Tecidual/imunologia , Grau de Desobstrução VascularRESUMO
Thirty-three patients with thrombosed peripheral arteries and bypass grafts, as confirmed by angiography, were treated with recombinant human tissue-type plasminogen activator (rt-PA). Twenty-six patients were treated with a dose of 0.1 mg/kg/hr and seven patients with 0.05 mg/kg/hr. Thrombus lysis and clinical improvement occurred in 22 of 26 (85%) patients in the 0.1 mg/kg/hr group. In seven of seven (100%) patients in the 0.05 mg/kg/hr group angiographic as well as clinical improvement were observed. Fifteen of the 33 patients required anticoagulation to maintain patency. Sixteen required secondary procedures to maintain patency. One (3%) patient required a blood transfusion for a hematoma at the catheter entry site. Three other patients developed small hematomas that were controlled without transfusion or intervention. Sixty-one percent of patients treated with the 0.01 mg/kg/hr dose and 86% of patients treated with the 0.05 mg/kg/hr dose maintained fibrinogen levels greater than 50% of their initial values. Infusion durations ranged from 1 to 6 hr (mean 3.9 hr). rt-PA appears to be a potent and selective thrombolytic agent that rapidly and safely lyses thrombi in peripheral arteries and occluded bypass grafts.
Assuntos
Oclusão de Enxerto Vascular/tratamento farmacológico , Proteínas Recombinantes/uso terapêutico , Trombose/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Adulto , Idoso , Feminino , Fibrinogênio/análise , Humanos , Perna (Membro)/irrigação sanguínea , Masculino , Pessoa de Meia-Idade , Proteínas Recombinantes/administração & dosagem , Fatores de Tempo , Ativador de Plasminogênio Tecidual/administração & dosagemRESUMO
Recombinant human tissue-type plasminogen activator (rt-PA) was infused intraarterially at 0.1 mg/kg/h for 1-6 1/2 hours in 25 patients with lower extremity thromboembolic occlusions (13 thrombosed arteries, 12 thrombosed bypass grafts). Occlusion duration ranged from 1 hour to 21 days. Thrombolysis occurred in 23 of 25 patients (92%). Time to lysis varied from 1 to 6.5 hours, with an average time of 3.6 hours. Twenty of 23 patients (87%) in whom thrombolysis was successful benefited clinically from thrombolytic therapy. Twelve of 23 patients (52%) required secondary procedures to maintain arterial segment patency. In 15 of 25 patients (60%) fibrinogen levels were maintained above 50% of baseline values. No major complications directly attributable to rt-PA infusions occurred. rt-PA is a potent, relatively fibrin-specific thrombolytic agent that can achieve rapid thrombolysis while usually avoiding the profound systemic fibrinogenolysis associated with currently available thrombolytic agents.
Assuntos
Fibrinolíticos/uso terapêutico , Oclusão de Enxerto Vascular/tratamento farmacológico , Proteínas Recombinantes/uso terapêutico , Trombose/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Adulto , Idoso , Prótese Vascular/efeitos adversos , Ensaios Clínicos como Assunto , Feminino , Fibrinogênio/análise , Humanos , Perna (Membro)/irrigação sanguínea , Masculino , Pessoa de Meia-Idade , Artéria Poplítea/diagnóstico por imagem , Radiografia , Fatores de TempoRESUMO
Twenty-nine patients with acute myocardial infarction were treated with recombinant human tissue-type plasminogen activator (rt-PA). The incidence of acute coronary reocclusion and its prevention by a maintenance infusion of rt-PA were studied. Intravenous rt-PA was given at a rate of 0.4 to 0.75 mg/kg over 60 to 120 min after angiographic documentation of complete coronary occlusion. Reperfusion was accomplished within 1 hr in 24 of 29 patients (83%) and was associated with a decrease of the plasma fibrinogen level by 20%. In a first group of 13 patients, 11 of whom were successfully reperfused, prevention of reocclusion was attempted with heparin anticoagulation. However, acute reocclusion within 1 hr after cessation of rt-PA was demonstrated angiographically in five of these patients (45%). Quantitative angiographic analysis indicated that acute reocclusion only occurred in patients with 80% or greater residual stenosis. In patients with less than 80% residual stenosis, heparin anticoagulation was sufficient to maintain patency during the hospital stay in four of five patients. In a second group of patients (n = 16), 13 of whom underwent reperfusion with intravenous rt-PA, seven demonstrated a residual stenosis of 80% or greater. These patients were given heparin and, in addition, 10 mg of rt-PA per hour for 4 hr. None developed acute angiographic reocclusion or clinical signs of reocclusion during the hospital stay. Repeat angiography at 10 to 14 days confirmed persistent patency in six of the seven patients. The maintenance infusion resulted in only a moderate additional drop in fibrinogen, while a steady-state plasma rt-PA level of 750 +/- 250 ng/ml was maintained.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Fibrinolíticos/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Ativador de Plasminogênio Tecidual/uso terapêutico , Doença das Coronárias/prevenção & controle , Fibrinolíticos/administração & dosagem , Humanos , Ativador de Plasminogênio Tecidual/administração & dosagemAssuntos
Ativador de Plasminogênio Tecidual/genética , Sequência de Aminoácidos , Animais , Ensaios Clínicos como Assunto , Clonagem Molecular , Fibrinolíticos , Humanos , Melanoma/enzimologia , Infarto do Miocárdio/tratamento farmacológico , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapêutico , Ativador de Plasminogênio Tecidual/uso terapêuticoRESUMO
Human tissue plasminogen activator holds promise for the dissolution of coronary thrombi by intravenous administration and without systemic anticoagulation. Prior animal experiments have been conducted only in vessels without disease. To test the thrombolytic efficacy of recombinant tissue plasminogen activator in the presence of diseased intima, an established model of atherosclerosis was utilized. The aorta of 16 New Zealand white rabbits (2 to 3 kg) was made atherosclerotic by balloon endothelial denudation and concurrent 1% cholesterol feeding for 8 weeks. An aged (24 hour) heterologous (human) clot, labeled with I-125 fibrinogen was injected into the distal aorta and produced thrombotic occlusion. After 1 hour of thrombosis (control period), recombinant tissue plasminogen activator (100,000 IU approximately equal to 1 mg protein, n = 6) or streptokinase (100,000 IU, n = 5) or saline solution (n = 5) was systemically infused over 30 minutes. Serial blood samples, obtained to determine fractional change in blood radioactivity over time, showed a fourfold increase of blood radioactivity after tissue plasminogen activator and streptokinase infusion compared with the control period (47,400 +/- 3,300 [mean +/- standard error] versus 11,800 +/- 300 counts/min, p less than 0.001). Time to 50% of maximal thrombolysis was 41 +/- 14 minutes (+/- standard deviation) for tissue plasminogen activator versus 63 +/- 16 minutes for streptokinase (p less than 0.01). In six of six rabbits receiving tissue plasminogen activator and four of five rabbits receiving streptokinase, reestablishment of distal aortic flow was detected via the indwelling catheter within 25 minutes of drug infusion.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Doenças da Aorta/tratamento farmacológico , Arteriosclerose/tratamento farmacológico , Ativadores de Plasminogênio/uso terapêutico , Trombose/tratamento farmacológico , Animais , Aorta Torácica/patologia , Doenças da Aorta/patologia , Arteriosclerose/patologia , Hemorragia/induzido quimicamente , Humanos , Infusões Parenterais , Masculino , Perfusão , Ativadores de Plasminogênio/administração & dosagem , Ativadores de Plasminogênio/efeitos adversos , Coelhos , Estreptoquinase/administração & dosagem , Estreptoquinase/efeitos adversos , Estreptoquinase/uso terapêutico , Trombose/patologiaRESUMO
The thrombolytic potency and myocardial infarct--sparing potential of recombinant tissue-type plasminogen activator (rt-PA) were studied in electrocardiographically monitored, open-chest, anesthetized dogs. Localized coronary thrombosis was produced in the left anterior descending artery by endothelial injury and instillation of thrombin and fresh blood. After 2 hr of stable thrombotic occlusion, rt-PA was infused intravenously. At a dose of 4.3 micrograms/kg/min, time to reperfusion was greater than 40 min (n = 3). However, at higher infusion rates a linear, dose-dependent time to coronary reperfusion was obtained (r = .88): at 10 micrograms/kg/min reperfusion occurred after 31 +/- 2 min (n = 3), at 15 micrograms/kg/min it was at 26 +/- 7 min (n = 4), and at 25 micrograms/kg/min, lysis was accomplished within 13 +/- 3 min (n = 3). Thrombolysis was not associated with alterations in either plasma hemostatic factors (fibrinogen, plasminogen, and alpha 2-antiplasmin) or in systemic blood pressures. Epicardial electrographic measurements revealed a significant reduction in ST elevation in all reperfused hearts. A randomized, blinded study was also carried out with 15 micrograms/kg/min of rt-PA saline in 18 dogs with 30 min of coronary thrombosis. Reperfusion in the treated group occurred after 28 +/- 3 min. No evidence of thrombolysis was noted in the saline-treated group within 240 min. Size of myocardial infarction was determined by triphenyl tetrazolium chloride staining and planimetry. Infarction involved 2.5 +/- 0.5% of the left ventricular wall in the group receiving rt-PA, but 16 +/- 3% of the left ventricle in the saline-treated group (p = .001). It is concluded that intravenous infusion of rt-PA results in rapid, dose-dependent coronary thrombolysis without systemic fibrinolytic activation and that early lysis of coronary thrombi is associated with substantial salvage of myocardial tissue.
Assuntos
Doença das Coronárias/tratamento farmacológico , Infarto do Miocárdio/tratamento farmacológico , Ativadores de Plasminogênio/uso terapêutico , Animais , Angiografia Coronária , Doença das Coronárias/diagnóstico por imagem , Modelos Animais de Doenças , Cães , Relação Dose-Resposta a Droga , Eletrocardiografia , Fibrinogênio/metabolismo , Fibrinólise/efeitos dos fármacos , Infarto do Miocárdio/diagnóstico por imagem , Plasminogênio/metabolismo , alfa 2-Antiplasmina/metabolismoRESUMO
IFN-alpha (rD) was investigated to determine the relationship between antiviral activity in vitro and the modulation of biologic effects in vivo. Eight patients with malignancy were given 15 and 45 micrograms weekly injections of IFN-alpha (rA) and IFN-alpha (rD). The frequency of side effects was much lower with IFN-alpha (rD) injections. This was objectively documented both in incidence of side effects (20 versus 45, p less than 0.01) and mean maximum temperature (1 degree C lower with IFN-alpha (rD), p less than 0.002). A bovine cell line, MDBK, was used to measure interferon concentrations in the serum. Geometric mean peak titers and time-to-peak titers were similar with the two recombinant interferon preparations. Although IFN-alpha (rD) has relatively less antiviral activity on human cells, its effect on the total granulocyte count, natural killer (NK) cell cytotoxicity, and 2'5'-A activity was comparable to IFN-alpha (rA). Mean NK cell percent specific 51Cr release was enhanced by both interferons (after 15 micrograms doses, mean percent NK cell cytotoxicity IFN-alpha (rD) preinjection, 10.5% +/- 2.3%; post-injection, 27.2% +/- 4.5%; IFN-alpha (rA), preinjection, 14.4% +/- 3.2%, postinjection, 25.1% +/- 5%). Species-specific antiviral activity of an interferon does not necessarily predict other biologic properties following in vivo administration.